Hyperbaric oxygen therapy peri-allo-HSCT

Current understanding

Hyperbaric oxygen therapy (HBOT) is being evaluated in an early-phase trial as a peri-transplant adjunct in patients undergoing allogeneic PBSC transplant for CMML, CNL, myelofibrosis, MDS/MPN overlap, and related myeloid malignancies. Endpoints span engraftment kinetics (notably neutrophil recovery), acute/chronic GVHD, and mucositis severity. This is an execution-layer intervention — it does not alter who should be transplanted or when, but represents a first-in-class, non-pharmacologic adjunct to standard supportive care and GVHD prophylaxis paradigms (evidence: trial-early).

Evidence log

• 2026-06-03 — Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant: cross-connection with peritransplant-ruxolitinib-gvhd: HBOT and peri-transplant JAK inhibitors represent parallel but mechanistically unrelated peri-transplant adjuncts targeting GVHD reduction; co-administration or sequencing has not been studied. (novelty: 4)

Open questions

Related